Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MECOM
REST API REST API
Homo sapiens
MECOM is differentially expressed in 308 experiments: 176 organism parts: liver, lung, ... (174 more);, 217 disease states: normal, prostate carcinoma, ... (215 more);, 99 cell types 441 cell lines 37 compound treatments and 80 other conditions.
Synonyms MDS1-EVI1, PRDM3, EVI1, MDS1
Orthologs mecom (Danio rerio)   Mecom (Rattus norvegicus)   MECOM (Bos taurus)   Mecom (Mus musculus)   MECOM (Gallus gallus)   CG10348 (Drosophila melanogaster)   ham (Drosophila melanogaster)   mecom (Xenopus laevis)   MECOM (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_BED_prd, Znf_C2H2, SET_dom
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, nuclear speck, apoptosis, negative regulation of programmed cell death, histone deacetylase complex, regulation of cell proliferation, intracellular, transcription, DNA-dependent, metal ion binding, nucleic acid binding, cell differentiation, positive regulation of transcription from RNA polymerase II promoter, regulation of cell cycle, response to bacterium, nucleus, negative regulation of JNK cascade, post-embryonic development, protein homodimerization activity, positive regulation of transcription, DNA-dependent, zinc ion binding, in utero embryonic development, embryonic hindlimb morphogenesis, forebrain development, pericardium development, embryonic forelimb morphogenesis, response to external stimulus, inflammatory response, neutrophil homeostasis, hemopoietic stem cell proliferation, sequence-specific DNA binding transcription factor activity
UniProt Accession Q9UBK3, Q8IU84, Q03112, D3DNP4, C9JU02, E7EQ57, E7EPY2, E7ERX0, E7EU48, E7EUL6, E9PGE9
Search EB-eye ENSG00000085276
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-1577, ... (35 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (44 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
SW480
3
E-MTAB-37, E-GEOD-18005, E-MEXP-1014
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MCF-7
2
E-GEOD-19639, E-GEOD-20081
435 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, ... (45 experiments)

Factor Value U/D Experiments
CD34+
2
E-AFMX-5, E-TABM-145
stromal cell
2
E-MEXP-2034, E-GEOD-1460
CXCR4 positive
1
E-GEOD-15893
CD8+ T cell
1
E-MTAB-25
not specified
1
E-GEOD-18811
double positive thymocyte
1
E-GEOD-1460
93 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (63 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
5
E-MTAB-62, E-MEXP-2034, E-GEOD-3868, E-MEXP-1327, E-TABM-26, ... (6 experiments)
colon carcinoma
3
E-GEOD-3726, E-MTAB-37, E-MTAB-62
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-GEOD-6014
lymphoma
2
E-MTAB-62, E-MTAB-37
myxoid liposarcoma
2
E-MTAB-62, E-GEOD-6481
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MTAB-62, E-MEXP-66
211 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-15205, E-GEOD-1417, E-TABM-782, E-GEOD-3720, ... (24 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-412, E-GEOD-5824, E-GEOD-1615, E-TABM-782, E-GEOD-1923, ... (7 experiments)
endotoxin
1
E-GEOD-3026
cooked broccoli
1
E-MEXP-1372
interferon-gamma + lipopolysaccharide
1
E-GEOD-7307
nocodazole
1
E-GEOD-6431
platelet-derived growth factor
1
E-GEOD-1923
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, ... (7 experiments)

Dfs follow up
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-10315, E-TABM-440, E-GEOD-837, E-GEOD-20505, E-TABM-263, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-20876, ... (33 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-17400, E-GEOD-6802 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-MEXP-1412, E-GEOD-1657, ... (8 experiments)

Pn
studied in E-GEOD-21653

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, ... (6 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.505 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM